GRIP1 Rabbit Polyclonal Antibody

CAT#: TA319860

Rabbit Polyclonal GRIP1 Antibody



Need it in bulk or conjugated?
Get a free quote

CNY 5,808.00


货期*
5周

规格
    • 100 ug

Product images

经常一起买 (2)
Transient overexpression lysate of glutamate receptor interacting protein 1 (GRIP1)
    • 100 ug

CNY 4,840.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00

Specifications

Product Data
Applications IF, IHC, WB
Recommend Dilution WB: 1 - 2 ug/mL
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Immunogen Rabbit polyclonal GRIP1 antibody was raised against a 17 amino acid peptide near the carboxy terminus of human GRIP1.
Formulation GRIP1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration 1ug/ul
Purification GRIP1 Antibody is affinity chromatography purified via peptide column.
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 118 kDa
Gene Name glutamate receptor interacting protein 1
Background GRIP1 Antibody: Glutamate receptors play an important role in neural plasticity, development and degeneration. The glutamate receptor interacting proteins, GRIP1 and GRIP2, members of the PDZ domain-containing protein family, mediate the trafficking and membrane organization of a number of transmembrane proteins. GRIP1 and GRIP2 specifically bind to the AMPA receptor subunits, GluR 2/3 and are involved in the targeting of GluR 2/3 to the synapse. GRIP1 is expressed in early development before the expression of AMPA receptors, while GRIP2 expression parallels that of AMPA receptors during later developmental stages. GRIP1 and GRIP2 may be involved in the induction of cerebellar long-term depression (LTD).
Synonyms GRIP
Reference Data
Protein Families Druggable Genome
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...